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Abstract 
A peptide hormone has been isolated from porcine intestine. Its primary structure was found to consist of 36 amino acid residues in a sequence 
identical to that of the porcine pancreatic polypeptide, previously not isolated from intestines or a tissue other than pancreas. The gut polypeptide 
significantly suppresses glucose-induced insulin secretion in vitro. Using an immunohistochemical technique, we also identified cells in the porcine 
gastrointestinal tract that were immunoreactive with pancreatic polypeptide. The immunoreactivity disappeared after absorption with the isolated 
gut polypeptide or synthetic human pancreatic polypeptide. 
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1. Introduction 
During studies on the isolation of chicken insulin, 
Kimmel et al. purified also another peptide from chicken 
pancreas and named it ‘pancreatic polypeptide’ (PP) [l]. 
Later studies showed that an analogous peptide was 
present in the pancreas of mammals [2]. PP was charac- 
terized as a 36-residue peptide with C-terminal tyrosine 
amide. The accumulated physiological and pharmaco- 
logical data indicated it to be a pancreatic hormone [3]. 
Homologous peptides have since been isolated and char- 
acterized from human, porcine, canine, bovine [4,5], rat 
[6], goose [7], alligator [8], turkey [9], ostrich [lo], chin- 
chilla [l 11, frog [12], four species of perissodactyla [13] 
and recently from five species of the Eurasian crow fam- 
ily [14] and from the European hedgehog [15]. In all 
studies reported so far, this peptide has been recovered 
only from the pancreas of these species. Furthermore, PP 
has been detected by immunofluorescence to occur in 
specific endocrine cells of the pancreas and gastrointesti- 
nal tract of man and rat, and, as judged by radioimmu- 
noassay, at different concentrations in the extracts of 
these tissues [16-181. However, we have not found any 
reports about the distribution of PP cells in porcine gut. 
*Corresponding author. Fax: (46) (8) 337 462. 
A previous report from our laboratories described the 
isolation of pancreatic secretory trypsin inhibitor (PSTI) 
from intestine [19]. Still earlier, the presence in intestine 
of the two 36-residue polypeptides PYY (Peptide YY) 
[20] and NPY (Neuropeptide Y) [21] were reported. Dur- 
ing the isolation of gut peptides that can influence insulin 
release, we have now purified the pancreatic polypeptide 
to high homogeneity and characterized it. The yield is 
about 3 pglkg of wet tissue. We also determined the 
distribution of porcine PP by an immunohistochemical 
method. 
2. Materials and methods 
2.1. Materials 
Carboxymethyl cellulose CM-23 and diethylaminoethyl cellulose 
(DEAE) DE-23 were from Whatman (Kent, UK), Sephadex G-25 (fine) 
from Pharmacia (Uppsala, Sweden), tosyl+phenylalanine chloro- 
methyl ketone-treated trypsin from Worthington (Freehold, NJ, USA), 
and avian pancreatic polypeptide from Peninsula Laboratories Europe 
(Merseyside, UK). 
2.2. Starting material 
The starting material was a concentrate of thermostable intestinal 
peptides prepared from the upper part of pig small intestine and frac- 
tionated with ethanol, as described [22-241. The ethanol precipitate at 
-20°C [24], 500 g (wet weight), was suspended in 5 1 sodium phosphate 
buffer (0.02 M, pH 6.4) containing 0.5% thiodiglycol. After vigorous 
stirring for 60 min, the insoluble material was removed by filtration and 
the clear tiltrate was passed through a column (14 x 14 cm) of carboxy- 
methyl cellulose, preequilibrated with the same buffer. Unretained ma- 
terial was precipitated by solubilization of 320 g NaCl/l after adjust- 
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Fig. 1. Exclusion chromatography of the crude material on Sephadex G-25 in 0.2 M acetic acid. Fraction 4 was collected and precipitated (cf. text). 
ment to pH 4.0 ?I 0.1 with 2 M HCl, and the precipitate was collected 
by suction filtration for further purification (cf. section 3). 
2.3. Bioassay 
The effects of peptide fractions on glucose-induced insulin release 
were monitored using isolated rat pancreatic islets [25]. Tissue cultures 
were maintained overnight at 37°C under 5% CO% and 95% air in 
medium RPM1 1640 (Flow Laboratories, Irvine, UK) containing 11 
mM glucose and 10% (v/v) heat-inactivated calf serum. After culture, 
insulin release was tested in batches of three islets in 300 ~1 Krebs- 
Ringer bicarbonate buffer, supplemented with 2 mg/ml bovine plasma 
albumin (fraction V, Sigma, St. Louis, MO, USA) and 10 mM HEPES 
(Sigma), pH 7.4, for 60 min at 37°C during shaking in a water bath. 
The incubation medium contained either 3.3 or 16.7 mM glucose, witb 
or without peptide fraction. After incubation, samples of the medium 
were taken for radioimmunoassay of insulin [26]. 
2.4. I~nohistochemical ~~vestig~t~o~ 
G~tro~~t~~ tract samples were taken from three months old 
pigs. Tissues from the gastric antropyloric region, upper and lower 
duodenum, jejuaum, ileum, colon, and pancreas were fixed in 10% 
buffered formalin overnight and routinely processed to pa&in. Sec- 
tions were incubated with polyclonal antisera against human synthetic 
PP (A619, Dakopatts, Glostrup, Denmark, diluted 1:lSOO) and stained 
[227]. To confirm the specificity of the PP-antiserum, an absorption test 
was made by incubation overnight at 48°C with 0.5, 2 and 10 nmol 
antigen per ml diluted antiserum. Antigens used were synthetic human 
pancreatic polypeptide (P-9903, Sigma, St. Louis, MO, USA) and the 
purified porcine gut polypeptide. 
2.5. Structural analysis 
Purity of peptide preparations was ascertained by thin-layer chrom- 
atography (TLC) on polyamide thin-layer sheets [22] and by capillary 
zone el~trophoresis with a Beckman P/ACE 2000 system, using coated 
capillaries of fused silica (inner diameter 100 pm, total length 27 cm) 
and 50 mM phosphate buffer, pH 2.5, as electrolyte. 
Molecular masses were determined with a plasma desorption time-of- 
flight mass spectrometer (Biolon). Samples were dissolved in 0.1% tri- 
fluoroacetie acid untying 20% acetonitrile, applied to ~~~ foil 
covered by nitrocellulose and dried in a stream of nitrogen. Data were 
accumulated for 15 min at 1.5 kV acceleration voltage. Hydrogen, so- 
dium and nitrous oxide were used as internal calibration stand- 
ards. 
Total compositions were determined with an LKB 4151 Alpha Plus 
amino acid analyxer after hydrolysis in evacuated tubes at 110°C for 
22 h with 6 M HCl containing 0.5% (w/v) phenol. Sequence analysis was 
carried out with an Applied Biosystems 470A instrument, and phen- 
ylthiohydantoin detection was by reverse-phase HPLC [28]. 
For C-terminal residue determination, 3Opg sample and 3Opg avian 
pancreatic polypeptide were dissolved in 30 ~1 1% NH,HCO,, respeo 
tively. A trypsin solution (2 pl; 5 mg/ml in 1 mM HCl) was added and 
the mixtures were incubated at 37°C for 2 h. After lyophiliiation, half 
of the digested material was analyzed by HPLC on a Vydac 218TP54 
(C,,) column (5 ,um, 4.6 x 250 mm). Remaining parts were analyzed by 
TLC as described above and developed with ninhydrin after migration 
for 4 h. 
3. Results and discussion 
A 2.50 g quantity of crude peptide mixture (the precip- 
itate after carboxymethyl cellulose-chromatography, cf. 
above) was dissolved in 2.5 1 0.2 M acetic acid, mixed 
with 50 g Hyfio and filtered by suction. The clear filtrate 
was chromatographed on Sephadex G-25 (35 x 135 cm) 
in 0.2 M acetic acid, giving five fractions (Fig. 1). Frac- 
tion 4 was saturated with NaCl (320 g/l) to produce a 
peptide precipitate which was collected by suction fhtra- 
tion (yield, about 25 g salt cake). A portion (10 g) was 
dissolved in 100 ml water, 200 ml 95% ethanol was 
added, and the solution was adjusted to pH 7.2 with 0.33 
M NaOH in 66% ethanol. The suspension was held at 
-2O’C for 48 h, and the precipitate was removed by 
suction filtration. To the tiltrate, an equal volume of 
ethanol, precooled to -2O”C, was added, and a precipi- 
tate was obtained after 24 h at -20°C. This precipitate 
Table 1 
Total composition of porcine gut pancreatic polypeptide 
Residue mol/mol 
Asx 3.2 (3) 
Thr 2.4 (2) 
Ser 
Glx 5.4 (5) 
Pro 4.6 (5) 
Gl Y 1.4 (1) 
Ala 4.6 (5) 
CYS 
Val 1.1 (1) 
Met 1.6 (2) 
Ile 1.0 (1) 
Leu 3.1 (3) 
Tyr 3.8 (4) 
Phe 
Trp - 
His 
LYS - 
Arg 4.4 (4) 
Values given are molar ratios from acid hydrolysis, without corrections 
for destruction, incomplete hydrolysis, or impurity, and, within paren- 
theses, from the sum of the sequence analysis. 
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Fig. 2. Reverse-phase HPLC of porcine gut PP. (A) The first HPLC 
step, from which the fractions were collected and lyophilizrxl for bioas- 
say (cf. text). The peak denoted by PP contained the gut pancreatic 
polypeptide. (B) Final purification of porcine gut PP. In both A and 
B, solvent B was acetonitrile with 0.1% trifluoroacetic acid. 
was collected by suction filtration (1.5 g wet weight), 
dissolved in 0.01 M NH4HC03, pH 8, chromatographed 
on a DEAE-column (3 x 25 cm) equilibrated with the 
same buffer, and eluted with stepwise increments to 0.05, 
0.1 and finally 0.2 M NH,HCO,. The fractions eluted 
with 0.1 M buffer were combined and lyophilized, pro- 
ducing 114 mg dry material. Aliquots (2 mg) were sub- 
jected to reverse-phase HPLC on TSK ODS 120-T (10 
,um, 7.8 x 300 mm) with a linear gradient (60 min, 1.5 
ml/mm) of 2650% acetonitrile in 0.1% trifluoroacetic 
acid. Eluted components absorbing at 214 nm were col- 
lected and analyzed (Fig. 2A). The fraction containing 
active material was further purified by chromatography 
on 4.6 x 250 mm Vydac 218TP54 (C,,) with a linear 
gradient (45 min, 1 rnl/min) from 30 to 45% acetonitrile 
in 0.1% trifluoroacetic acid. The active peptide compo- 
nent (Fig. 2B) gave one spot upon TLC, and one sym- 
metrical peak upon capillary zone electrophoresis (Fig. 
3). It was found to correspond to porcine gut PP as 
identified by sequence analysis (below). The yield was 
about 3 &kg pig intestine (wet). 
Plasma desorption mass spectrometry (PDMS) with 
50 pmol purified gut peptide revealed two prominent 
peaks at mlz 2098.5 and 4194.3, corresponding to the 
doubly and singly charged species (Fig. 4), resulting in 
an average mass for this peptide of 4193 f 4 Da. This 
mass agrees well with the calculated mass for porcine 
pancreatic polypeptide, 4196.8 Da [3]. 
The amino acid sequence of gut PP was determined by 
Edman degradation. Using 300 pmol, the results were 
interpretable up to cycle 36, and in agreement with the 
structure of porcine pancreatic polypeptide [3]. Molecu- 
lar weight determination and amino acid analysis (Table 
1) showed the C-terminal residue to be tyrosine. The 
precision of PDMS in this mass range is insufficient for 
determination of whether the tyrosine residue is free or 
amidated. Therefore, tryptic digestions of purified gut 
polypeptide and avian pancreatic polypeptide, the latter 
containing known C-terminal Arg-Tyr-amide, were car- 
ried out, followed by HPLC and TLC analyses. HPLC 
retention time and TLC Rf value, in relation to standard 
tyrosine and tyrosine amide, clearly showed that the pig 
gut polypeptide has a C-terminal tyrosine amide, identi- 
cal to the C-terminal structure of avian PP. 
Pancreatic polypeptide-immunoreactive c lls (PP-IR) 
were found in the mucosa of the antropyloric and duode- 
nal regions, and also in some Brunner gland cells. The 
pancreas contained a large amount of PP-IR cells (Fig. 
5), while no PP-IR cells were identified in the jejunum or 
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Fig. 3. Capillary zone electrophoresis of gut PP, with inset showing 
thin-layer chromatography on a silica gel plate. Amount applied to 
electrophoresis was 10 pmol; 4 nmol was applied to the silica gel plate. 
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ileum, although frequently in the colonic mucosa. The 
adsorption test with antigens to both human PP and the 
porcine gut polypeptide totally abolished the im- 
munoreactivity. In early reports, human PP-cells were 
mainly found in the pancreas, but a small amount of 
PP-immunoreactive cells were found throughout the gas- 
trointestinal tract [16]. In adult rats, PP-cells were re- 
ported to occur only in the colon and pancreas [17]. In 
our study, the biochemical and immunohistochemical 
results support each other and strongly suggest that the 
small amount of extracted peptide originates from PP- 
producing cells in the upper part of the intestine. 
The secretion of insulin from isolated islets was almost 
three-fold higher at 16.7 mM than at 3.3 mM glucose 
(58.9 f 3.2 vs. 20.5 + 1.2 pU/islet per h, n = 8, 
P C 0.001). Addition of the purified gut polypeptide (100 
nM) to 16.7 mM glucose suppressed the insulin release 
to 31.8 + 1.8,Dlislet per h (n = 8, P < 0.001). Thus, the 
gut peptide inhibited stimulated insulin secretion by 
46%. Inhibition of the stimulated insulin secretion has 
previously been shown in vivo with bovine PP in mice 
[29] and dogs [30,2], and with rat and human PP in rats 
[31,32]. For porcine PP, data have appeared conflicting 
since this peptide suppressed insulin secretion in dogs 
[33] but not in rats [34]. It is possible, however, that this 
previously apparent difference was accounted for by the 
administration of larger, pharmacological, amounts of 
PP in most studies, showing an effect on the insulin 
release, while smaller amounts of PP were infused in the 
second study [34]. In this context, it is of interest hat the 
gut PP, as now shown, exerts a direct insulin-suppressive 
effect on the isolated pancreatic islet. 
In conclusion, we have isolated PP from porcine intes- 
tine, demonstrated its primary structure to be identical 
with that for porcine PP from pancreas, established the 
PP distribution in pig gut and shown a suppressive ffect 
of PP in vitro on insulin secretion from rat endocrine 
I In I 
~“V”” 
I 
(M:H,++ Fig. 5. Photomicrographs of (top) a section from porcine antropyloric 
region with a single cell (black) immunoreactive toPP antigen; (middle) 
z 0 30000 
a PP-immunoreactive c ll (black) in the gland of Brunner from a section 
- of porcine duodenum submucosa; and (bottom) a section from porcine 
Y pancreas with PP-immunoreactive cells (black) at well-known posi- 
I tions. 
E I “““L (M+H)+ 1 I pancreas. With the establishment of PP production in the 
gut, the PP actions in the intestinal system will now be 
available for further investigation to determine the phys- 
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Fig. 4. PDMS spectrum of porcine gut PP after application of 50 pmol 
to a nitrocellulose-covered aluminized mylar target. 
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